Hossfeld, Dieter K.

A
- (DIERLAMM, J., MURGA PENAS, E. M., DAIBTA, M., TAGUSHI, H., HINZ, K., BAENS, M., COOLS, J., SCHILLING, G., MICHAUX, L., MARYNEN, P., MIYOSHI, I., HOSSFELD, D. K.) The novel t(11;12;18)(q21;q13;q21) represents a variant translocation of the t(11;18)(q21;q21) associated with MALT-type lymphoma. - Leukemia 16, S. 1863-1891.
- (WEBER, M., GERDSEN, F., GUTENSOHN, K., SCHODER, V., EIFRIG, B., HOSSFELD, D. K.) Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. - Thrombosis Res. 107, S. 325-328.
- (LAACK, E., KÖHLER, A., KUGLER, C., DIERLAMM, T., KNUFFMANN, C., VOHWINKEL, G., NIESTROY, A., DAHLMANN, N., PETERS, A., BERGER, J., FIEDLER, W., HOSSFELD, D. K.) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. - Ann. Oncol. 13, S. 1550-1557.
- (LAACK, E., MENDE, T., DÜRK, H., KNEBA, M., DICKGREBER, N., WELTE, T., MÜLLER, T., SCHOLTZE, J., GRAEVEN, U., JASIEWICZ, Y., EDLER, L., HOSSFELD, D. K. ) Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell trans-plantation in mice. - Int. J. Cancer 98, S. 785-792.
- (LAACK, E., MENDE, T., DÜRK, H., KNEBA, M., DICKGREBER, N., WELTE, T., MÜLLER, T., SCHOLTZE, J., GRAVEN, U., JASIEWICZ, Y., EDLER, L., HOSSFELD, D. K.) Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: A phase II trial. - Eur. J. Cancer 38, S. 654-660.
- (IYER, L., RAMÍREZ, J., SHEPARD, D. R., BINGHAM, C., HOSSFELD, D. K., RATAIN, M. J., MAYER, U.) Biliary transport of irinotecan and metabolites in normal and p-glycoprotein deficient mice. - Cancer Chemother. Pharmacol. 49, S. 336-341.
- (TUINMANN, G., SCHILLING, G., BRETTNER, S., HEGEWISCH-BECKER, S., HOSSFELD, D. K.) Darminvagination als Folge einer intraabdominellen Manifestation eines großzelligen Non-Hodgkin-Lymphoms. - Med. Welt 1.
- (KÖHNE, C. H., VANHOEFER, U., HOSSELD, D. K., HÖFFKEN, K., SEEBER, S.) Therapie des metastasierten kolorektalen Karzinoms mit 5-FU/Folinsäure und Irinotecan. - Deutsch. Ärztebl. 5, A292-294.
- (LAACK, E., NIKBAKHT, H., PETERS, A., KUGLER, C., JASIEWICZ, Y., EDLER, L., HOSSFELD, D. K., SCHUMACHER, U.) Lectin histochemistry of resected adenocarcinoma of the lung. - Amer. J. Pathol. 160, S. 1001-1008.
- (HEGEWISCH BECKER, S., GRUBER, Y., COROVIC, A., PICHLMEIER, U., ATANACKOVIC, D., NIERHAUS, A., HOSSFELD, D. K.) Whole body hyperthermia (41,8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour con-tinuous infusion in pretreated metastastic coloreactal cancer: A phase II study. - Ann. Oncol. 13, S. 1197-1204.
- (LANGER, F., BERGMANN, F., BUDDE, U., HEGEWISCH-BECKER, S., HOSSFELD, D. K.) Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. - Brit. J. Hamatol. 118, S. 271-274.
- (LANGER, F., EIFRIG, B., HEGEWISCH-BECKER, S., MARX, G., NEUBER, K., HOSSFELD, D. K.) Kompliziertes Antiphospholipidantikörper-Syndrom. - Dtsch. Med. Wschr. 127, S. 1458-1462.
- (ATANACKOVIC, D., NIERHAUS, A., NEUMEIER, M., HOSSFELD, D. K., HEGEWISCH-BECKER, S.) 41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases. - Cancer Immunol. Immunother. 51, S. 603-613.
- (LAACK, E., DIERLAMM, T., KNUFFMANN, C., POPP, J., SCHMIED, B., DÜRK, H., WACKER-BACKHAUS, G., ZELLER, W., VERPOORT, K., FIEDLER, W., HOSSFELD, D. K.) Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. - Lung Cancer 36, S. 303-307.
- (JOSTING, A., RUDOLPH, C., REISER, M., MAPARA, M., SIEBER, M., KIRCHNER, H. H., DÖRKEN, B., HOSSFELD, D. K., DIEHL, V., ENGERT, A. & participating centers) Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodkin's disease. - Ann. Oncol. 13, S. 1628-1635.
- (LANGER, F., EIFRIG, B., MARX, G., STORK, A., HEGEWISCH-BECKER, S., HOSSFELD, D. K.) Exacerbation of antiphospholipid antibody syndrome after treatment of localized cancer: A report of two cases. - Ann. Hematol. 81, S. 727-731.
- (KAISER, U., UEBELACKER, I., ABEL, U., BIERMANN, J., TRÜMPER, L., SCHMALENBERG, H., KARAKAS, T., METZNER, B., HOSSFELD, D. K., BISCHOFF, H. G., FRANKE, A., REISER, M., MÜLLER, P., MANTOVANI, L., GRUNDEIS M, ROTHMANN F, VON SEYDEWITZ CU, MESTERS RM, STEINHAUER EU, KRAHL, D., SCHUMACHER, K., KNEBA, M., BAUDIS, M., SCHMITZ, N., PFAB, R., KÖPPLER, H., PARWARESCH, R., PFREUNDSCHUH, M., HAVEMANN, K.) Randomized study to evaluate the use of highdose therapy as part of primary treatment for ‚aggressive' lymphoma. - J. Clin. Oncol. 20, S. 4413-4419.
- (LAACK, E., NIKBAKHT, H., PETERS, A., KUGLER, C., JASIEWICZ, Y., EDLER, L., BRÜMMER, J., SCHUMACHER, U., HOSSFELD, D. K.) Expression of CEACAM1 in adenocarcinoma of the lung: A factor of independent prognostic significance. - J. Clin. Oncol. 21, S. 4279-4284.